Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

Inclusion Criteria: * Confirmed diagnosis of primary or metastatic intrahepatic carcinoma * The cancer must be unresectable with limited established treatment options * ECOG Performance Status Score 0-2 * Age 19 years or older * Able to comprehend and provide written informed consent Exclusion Criteria: * Any pre-treatment laboratory findings within 15 days of treatment demonstrating: * Absolute granulocyte count ≤ 1,500/ul * Platelet count ≤ 75,000/ul * Serum creatinine \> 2.0 mg/dl * Serum bilirubin ≥ 2.0 mg/dl * Any of the following contraindications to angiography and selective visceral catheterization: * History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine * Bleeding, diathesis, not correctable by usual forms of therapy * Severe peripheral vascular disease that would preclude catheterization * Substantial venous shunt away from the liver * Evidence of potential delivery of greater than 11 mCi (20 Gy absorbed dose) of radiation to the lungs on either 1) first Therasphere® administration; or 2) cumulative delivery of radiation to the lungs over multiple treatments * Evidence of any detectable Tc-99 MAA flow to the stomach or duodenum, application of established angiographic techniques to stop such flow * Significant extrahepatic disease representing an imminent life- threatening situation outcome * Severe liver dysfunction or pulmonary insufficiency * Active uncontrolled infection * Significant underlying medical or psychiatric illness * Pregnant women may not participate